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Abstract
Background: Peritoneal carcinomatosis (PC) is a common
endpoint in both gastrointestinal and non-gastrointest-
inal cancers, and PC is treated as other systemic metas-
tases – unfortunately with disappointing results and
considerable side-effects. Pressurized IntraPeritoneal
Aerosol Chemotherapy (PIPAC) is a new method of apply-
ing traditional chemotherapy, and preliminary data indi-
cate that PIPAC is safe, able to stabilize or improve
quality of life, and can induce an objectively measurable
reduction in disease burden in PC.
Methods: PIPAC-OPC2 is a prospectively controlled Phase
II, single center, one-arm, open-label clinical trial inves-
tigating the treatment effect of PIPAC in patients with
histological or cytological proven PC from gastrointest-
inal, ovarian or primary peritoneal cancer. Eligible
patients will receive PIPAC in series of three using a
combination of doxorubicin (1.5mg/m2) and cisplatin
(7.5mg/m2) for non-colorectal cancer patients (PIPAC
C/D), and oxaliplatin (92mg/m2) in patients with PC of
colorectal origin (PIPAC OX). Patients are monitored by:
(1) repeated measurements of the Peritoneal Regression
Grading Score (PRGS) in biopsies obtained from metal
clips marked areas, (2) Quality-of-Life (QoL) question-
naires, (3) Magnetic Resonance Imaging (MRI) and (4)
Prognostic Nutritional Index (PNI). Adverse events and
surgical complications will be recorded according to the
30 days definition.
Results: The primary outcome of PIPAC-OPC2 is to eval-
uate if PIPAC can induce major or complete response
(PRGS 1 or 2) within a series of three PIPAC procedures.
Secondarily this study investigates changes in QoL and
MRI as a staging and response evaluation tool. The sec-
ondary outcomes will be used to create a model that may
predict which of the patients will benefit from PIPAC
treatment.
Conclusions: It is expected that PIPAC directed therapy
can induce major or complete response in 50% of
patients with PC of colorectal origin and in 30% of
patients with PC of non-colorectal origin – and at the
same time stabilize or even improve quality of life. This
trial may provide data regarding the utility of MRI as a
staging and response evaluation tool in patients with PC.
Trial registration: The study is registered with
ClinicalTrials.gov Identifier NCT03287375 and the
European Clinical Trials Database (EudraCT) number
2016-003394-18.
Keywords: MRI, peritoneal carcinomatosis, peritoneal
regression grading score (PRGS), PIPAC, quality of life,
response evaluation.
Introduction
Peritoneal carcinomatosis (PC) represents end stage dis-
ease in many types of cancer (e.g. gastric, pancreatic,
liver, colo-rectal, ovarian) and, if left untreated, the
majority of patients with PC will die from their disease
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within 6 months [1]. Platinum-based systemic chemother-
apy (SC) may prolong survival in selected patients, but
poor performance status and low response rates have led
to nihilistic treatment strategies in these patients.
However, patients with PC who are in good condition
and with a remaining life expectancy of more than a
few months, may still have an unmet need for additional
treatment in order to be able to perform with a high
quality of life for as long as possible. These patients
have often tried several lines of SC with disappointing
results, and alternative and more effective treatment stra-
tegies are needed.
The installation of chemotherapeutic agents within
the peritoneal cavity would seem a simple and effective
treatment of PC – at least from a theoretical point of view.
Unfortunately, the effect of intraperitoneal chemotherapy
on PC is disappointing. Like with SC, the poor response
rates may be explained by the poor penetration of the
active chemical substances into the PC plaques [2].
Combining cytoreductive surgery (CRS) with hyperther-
mic intraperitoneal chemotherapy (HIPEC) has gained
interest in recent years, but this approach can only be
used in highly selected patients and carries a significant
risk of complications and side effects [1]. Thus, a mini-
mally invasive and safe delivery of relevant chemother-
apeutics in concentrations that allow it to work efficiently
on the PC plaques would be an ideal tool for a new
treatment strategy in these patients.
Pressurized IntraPeritoneal Aerosol
Chemotherapy (PIPAC)
PIPAC has been established as a new drug delivery sys-
tem that may be used in patients with PC. PIPAC is a safe
procedure [3, 4] with a very low adverse events profile
[5–7], and although no Phase III studies have been pub-
lished so far, the preliminary clinical experience seems
promising in patients with PC from several different types
of primary cancers [8]. A recent international survey
study showed that the PIPAC procedure, the time
between procedures and the chemotherapy protocols
were similar in most centers [9]. However, the methods
used to evaluate disease burden before, during and after
PIPAC-directed treatment (i.e. treatment response) were
more inhomogeneous. Traditional staging tools (e.g. CT
and PET-CT) have been validated for status at the time of
surgery, not for the progression/regression of PC at
repeated laparoscopic procedures. With these limitations
in mind, Sugarbaker’s Peritoneal Cancer Index (PCI) is
used as a surrogate marker for treatment response,
whereas repeated biopsies for histologic analysis are
more seldom used [9].
Peritoneal Regression Grading Score (PRGS)
and peritoneal lavage fluid examination
In 2016 an international expert pathology group suggested
the use of a Peritoneal Regression Grading Score (PRGS) to
evaluate biopsies during PIPAC-directed treatment [10],
but data comparing baseline PRGS with PRGS in biopsies
retrieved at the third PIPAC procedure are still lacking.
When looking at the peritoneal fluid, free intraperitoneal
tumor cells (FITC) detected during peritoneal lavage seem
associated with a poor prognosis in various cancer types
(e.g. gastric cancer) [11]. By combining conventional cytol-
ogy (with immunocytochemistry, if needed), protein ana-
lysis and reverse transcriptase polymerase chain reaction
(RT-PCR) for carcinoembryonic antigen (CEA) mRNA, the
conversion rate from FITC positive to FITC negative
patients may be assessed, and thus provide an additional
marker for the effect of PIPAC directed therapy.
MRI
In a recent study of patients with ovarian cancer, diffu-
sion-weighted MRI, PET-CT and CT were compared with
perioperative findings at diagnostic laparoscopy. When
comparing the size and location of PC, MRI had an accu-
racy of 0.94, compared to 0.75 and 0.71 for CT and PET-CT
[12]. When comparing PCI scores between preoperative
combined diffusion-weighted and gadolinium-enhanced
MRI and PCI scores obtained during laparotomy the sensi-
tivity of MRI was 0.88 and the specificity 0.74 [13]. In a
recent, relatively small retrospective study, the same group
presented a sensitivity of 0.95 and a specificity of 0.70
when comparing PCI scores from combined diffusion
weighted and gadolinium enhanced MRI with PCI scores
during laparotomy [14]. Based on these results, diffusion-
weighted and gadolinium enhanced MRI seems to be able
to predict the PCI score, but it is unknown if it can be used
as a tool in the response evaluation.
Prognostic Nutritional Index
PC is perceived as end-stage disease and some of the
referred patients are beyond therapeutic reach. To
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ensure optimal patient selection, the need for an initial
low-cost analysis without side effects seems obvious.
Based on the total lymphocyte count and serum albu-
min level, the Prognostic Nutritional Index (PNI) is
correlated to postoperative complications and long
term prognosis in patients with gastric cancer
(10 × serum albumin value (g/dl) + 0.005 × lymphocyte
count in peripheral blood) [15, 16]. In a study of 248
gastric cancer patients, a low PNI correlated with more
advanced tumor size, nodal involvement and venous
and lymphatic invasion. By dividing the patients into
two groups according to the mean PNI (49.7), the 1, 3
and 5 year survival was significantly lower in the group
with a low PNI (87.4%, 72.9% and 67.7% compared to
98.3%, 93.3% and 86.5%, respectively) [17]. When
using a cut-off point of 46 in a population of gastric
cancer patients, the PNI-low group had more advanced
tumors according to TNM, and the PNI-low group had
more often postoperative complications [16]. Based on
these data, PNI could be a potential prognostic factor in
gastrointestinal cancer patients, but it is unknown
whether it is useful in the palliative setting of patients
with PC.
Quality of Life (QoL)
Health-related QoL has become an increasingly accepted
and necessary endpoint in clinical cancer trials [18]. A
recent review suggested that QoL could be maintained
during PIPAC-directed therapy and also improved in spe-
cific symptoms or functions scores [8]. However, more
prospective data are needed to pinpoint the potential
impact of PIPAC in specific symptoms or functions
scores.
Materials and methods
The primary aim of this trial is to evaluate if PIPAC can induce
major or complete response (PRGS 1 or 2) within a series of three
PIPAC procedures in patients with PC from gastrointestinal, ovar-
ian or primary peritoneal cancer. Secondary aims include monitor-
ing of potential changes in QoL during the course of PIPAC
treatment and assessment of the utility of MRI for the pre- and
post-PIPAC evaluation of treatment response. A series of demogra-
phical data and additional variables (e.g. Prognostic Nutritional
Index, PNI) obtained during the study will subsequently be used to
create a model that predicts who may benefit from PIPAC
treatment.
Recruitment process
Patients with PC from gastrointestinal, ovarian or primary perito-
neal cancer are eligible for inclusion (Table 1). Prior to inclusion,
the patients will be discussed at a dedicated multi-disciplinary
tumor conference (MDT) in order to plan the best treatment strat-
egy (e.g. PIPAC monotherapy or bidirectional therapy) and to rule
out other standard treatment alternatives (Figure 1).
Study intervention
Included patients will be scheduled for three PIPAC procedures
(PIPAC C/D or PIPAC OX) with intervals of 4–6 weeks or 6–7
weeks if bidirectional treatment is provided.
Table 1: Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
– Histologically or cytologically verified gastrointestinal or ovarian
cancer or primary peritoneal malignancy (based on tissue from the
primary tumor and/or its metastases)
– Ovarian cancer patients must be platinum resistant and have
completed at least one line of chemotherapy for platinum-resistant
disease
– Radiological, histological or cytological evidence of PC
– No indication for CRS and HIPEC (according to National Guidelines).
– Performance status –
– No more than one extraperitoneal metastasis
– Age > years
– Females must be post-menopausal
– Written informed consent
– Symptomatic small bowel obstruction (i.e. total parenteral
nutrition, nasogastric tube)
– Previous treatment with maximum cumulative doses of
doxorubicin, daunorubicin, epirubicin, idarubicin, and/or other
anthracyclines and anthracenediones
– A history of allergic reaction to platinum containing compounds or
doxorubicin
– Renal impairment, defined as glomerular filtration rate (GFR) < 
mL/min, (Cockcroft-Gault Equation)
– Myocardial insufficiency, defined as NYHA class >
– Impaired liver function defined as bilirubin ≥ . ×UNL (upper
normal limit)
– Inadequate hematological function defined as ANC ≤ . ×/L
and platelets ≤ ×/L
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MRI
An MRI is performed at the Odense PIPAC Center (OPC) prior to the
first and after three PIPAC procedures. All MRIs are performed
according to a specific protocol: During the last 90–120 min before
MRI exam, the patient drinks 700–1000 mL of pineapple juice, and
just prior to the examination, 1mg glucagon (GlucaGen®) is admi-
nistered subcutaneously to reduce small bowel motion. Using digital
phased-array coils on an Achieva dStream 1.5T MRI system (Philips,
the Netherlands), patients are examined as follows:
1. Free breathing diffusion weighted sequences with STIR Fat Sat,
b-values 0, 400, 800, 1500.
2. Respiratory triggered TSE T2 sequences in two planes of upper
and lower abdomen.
3. Breath hold, 3D mDixon FFE in two planes following injection
of intravenous contrast (Gadovist®).
The MRI scans will be interpreted and PCI scored by two indepen-
dent experienced MR radiologists – both blinded to the laparoscopic
PCI scorings.
Laparoscopy, peritoneal biopsies and assessment of
PRGS
During each laparoscopy and prior to the PIPAC procedure, PCI
scoring is documented and the parietal peritoneum biopsied in all
four quadrants (if possible). To minimize the risk of sampling error
during repeated biopsies, small metal clips are used to mark the site
of biopsy. The surgeons are blinded to the results of the MRI scans.
The biopsies will be fixed in formalin and embedded in paraffin,
followed by step-section at three levels, which will be stained with
H&E. Microscopically, they are evaluated according to the PRGS [10].
In short, PRGS1 equals complete histological response and is defined
as the absence of residual cancer and large amount of regressive
fibrosis (and/or acellular mucin pools and/or infarct-like necrosis),
PRGS2 is defined as a specimen where regressive changes are pre-
dominant over cancer cells, PRGS3 as a specimen where regressive
changes are present but where cancer cells are predominant over
fibrosis, and PRGS4 as a specimen without histological features of
regression. In addition to the recommendation just mentioned, one
section will be stained immunohistochemically for the tumor cell
marker EP4, followed by another three step sections stained with
H&E, as described previously (Prospective, single-center implemen-
tation and response evaluation of Pressurized Intraperitoneal
Aerosol Chemotherapy (PIPAC) for peritoneal metastasis, Ther Adv
Med Onc, accepted March 2018). If present, the type of necrosis will
also be recorded. Infarct- or mucin-like necrosis will be regarded as
indicative of regression, whereas usual necrosis will be regarded as
indicative of a lack of response in the respective area, as described
for colorectal liver metastases [19]. In the pathology report, a PRGS
for each quadrant biopsy will be given, as well as a mean PRGS.
Peritoneal lavage and cytologic analysis
Peritoneal cytology will be assessed by analysis of evacuated ascites or
fluid obtained by peritoneal lavage prior to the PIPAC procedure. At
least 100 mL peritoneal lavage fluid will be sent to the Department of
Pathology, along with the biopsies, and processed as described pre-
viously (Prospective, single-center implementation and response eva-
luation of PIPAC for peritoneal metastasis, Ther AdvMed Onc, accepted
March 2018). In short, the fluid will be centrifuged, and smears of the
sediment will be analyzed by conventional cytology (Papanicolaou and
May-Giemsa Grünwald staining). Leftovers of the sediment are
embedded in paraffin wax and one section will be stained with H&E.
If necessary, further sections will be cut for immunocytochemical ana-
lyses for markers such as calretinin, CDX2, carcinoembryonic antigen
(CEA), cytokeratin (CK) 7, CK20, Ep-CAM, Pax8 ormaspin. In the pathol-
ogy report, a five-tiered score will be used: malignant cells, suspicious
cells, atypical cells, no malignant cells, other.
PIPAC
All PIPAC procedures will be performed laparoscopically using two
standard trocars where the insufflation of normothermic CO2 maintains
an intraabdominal pressure of 12 mmHg. To reduce the risk of access
lesions, a transabdominal ultrasound will be performed at the start of
each procedure. Following standard prophylactic antibiotics, PIPAC is
performed using doxorubicin 1.5mg/m2 body surface in 50 mL NaCl
0.9% and cisplatin at a dose of 7.5mg/m2 body surface in 150 mL NaCl
0.9% (1/10 of systemic dose). In patients with PC of colorectal origin,
PIPAC is performed with oxaliplatin 92mg/m2 in 150 mL dextrose.
Chemotherapy is installed at a rate of 30 mL/min with a maximum
pressure of 200 PSI and after five minutes, the chemotherapy has been
delivered, and the injector is turned off. After an additional 25 min of
simple diffusion, the intraabdominal air saturated with chemotherapy
is evacuated in a closed system through a standard trocar.
Chemotherapy used in this study is standard, commercially avail-
able antineoplastic drugs, and they are part of the general assort-
ment of the hospital pharmacy. The used drugs are traceable
through the hospital pharmacy’s unique batch number and through
Patients with PC referred
for PIPAC
File evaluation by PI
MDT meeting
MRI
Exclusion based on in-/exclusion
criteria
MRI and CT
Informed consent
PIPAC (3 series, q4–7
weeks)
Figure 1: Patient flow chart.
MDT, multi-disciplinary tumor conference; PC, peritoneal carcino-
matosis; PI, principal investigator; PIPAC, Pressurized
IntraPeritoneal Aerosol Chemotherapy.
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a patient specific chemotherapy prescription. Dose modification is
not relevant in the cisplatin plus doxorubicin group. Dose modifica-
tion in the oxaliplatin group will be done according to Table 2.
Post procedure monitoring
Postoperative monitoring and treatment of nausea, vomiting and
pain will be according to departmental guidelines. The patient will
be discharged the same day or the first day after the PIPAC proce-
dure, but hospitalization up to three days is considered acceptable.
Adverse medical events will be graded according to Common
Terminology Criteria for Adverse Events (CTCAE, version 4.0), and
surgical related complications according to the Dindo-Clavien clas-
sification. The active reporting period begins, when the patient is
admitted for the first PIPAC procedure and stops 30 calendar days
after the last PIPAC procedure.
Quality of life questionnaires will be collected at baseline and
after 4 months using the EORTC QLQ-C30 questionnaire.
Study design
This study is a prospectively controlled Phase II, single center, one-
arm, open-label clinical trial for patients with histological or cytolo-
gical proven PC from gastrointestinal or ovarian cancer or patients
with primary peritoneal cancer.
Ethical declarations
This study is GCP monitored and has been approved by the Regional
Scientific Ethical Committees for Southern Denmark (IRB S-20160100)
and the Danish Medicines Agency (code no 2016083464, EudraCT
number 2016-003394-18). Oral and written consent from participants
are mandatory.
Statistics
Values are given as means or medians where appropriate. Categorical
data will be specified with 95% confidence intervals, comparisons
will be performed using non-parametric tests, all p-values are two-
tailed and a p-value of 0.05 will be considered statistically significant.
Prognostic factors indicating survival will be analyzed in a multi-
variable logistic regression model. Survival will be modelled in
Kaplan-Meier survival curves. Baseline MRI interrater reliability will
be analyzed using Cohen’s kappa statistics.
An interim analysis will be performed every 6 months.
Complications leading to treatment under general anesthesia
(Dindo-Clavien ≥ 3b), serious adverse events in more than 10% of
the included patients or a 30 days’ mortality > 15% terminates the
study. Median overall survival will be calculated annually, and if it
is < 6 months, the study will be stopped.
Results and discussion
Hypothesis and power calculation
The hypothesis is that PIPAC will induce a response in PC
patients, and that this may be monitored by a change in the
histological response evaluation. Based on the relatively few
available data on PIPAC it seems relevant to divide the PC
patients into two groups according to their primary cancer
disease (“Colo-rectal” and “Other”), and touse this approach
for the calculation of the number of patients needed.
1. Colorectal cancer patients with PC: We expect
major or complete histologic response (mean PRGS 1 or
2) in 30% after SC. After a maximum of three PIPAC
series, we expect major or complete response in 50%.
With an estimated 10% dropout, we will include 55
patients (α: 0.05, Power: 0.8).
2. Other cancer patients with PC: We expect major or
complete histologic response (mean PRGS 1 or 2) in 15%
after SC. After a maximum of three PIPAC series, we expect
major or complete response in 30%.With an estimated 10%
dropout, we will include 82 patients (α: 0.05, Power: 0.8).
Author contributions: All the authors have accepted
responsibility for the entire content of this submitted
manuscript and approved submission.
Study schedule: The trial started inclusion of patients in
December 2016. The last patient is estimated to be
included and treated by the end of May 2021. All data
generated or analyzed during this study will be included
in the published article(s).
Trial organization: The trial is organized by Odense
PIPAC Center (OPC) which is a multi-disciplinary cancer
group based at Odense University Hospital.
Research funding: This study was funded by Odense
PIPAC Center, Odense University Hospital, 5000 Odense,
Denmark.
Table 2: Oxaliplatin dose modification.
Adverse
reaction
Action
Grade  No modification
Grade  If the toxicity is tolerable for the patient, the planned
treatment will continue. If the toxicity is poorly
tolerated, the dose of oxaliplatin will be reduced to
%
Grade  The treatment will be postponed until the toxicity is
below grade . After this, oxaliplatin can be given in
a dose of %
Grade  Stop treatment. Treatment can be reinstituted at the
discretion of the responsible physician, if the
adverse reaction falls below Grade 
Graversen et al.: PIPAC treatment in patients with peritoneal carcinomatosis 5
Brought to you by | University Library of Southern Denmark - Syddansk Universitetsbibliotek
Authenticated
Download Date | 10/29/18 9:16 AM
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played
no role in the study design; in the collection, analysis
and interpretation of data; in the writing of the report; or
in the decision to submit the report for publication.
References
1. Coccolini F, Gheza F, Lotti M, Virzi S, Iusco D, Ghermandi C, et al.
Peritoneal carcinomatosis. Wjg 2013;19:6979–94.
2. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive
surgery for the prevention and treatment of peritoneal carcino-
matosis and sarcomatosis. Semin Surg Oncol 1998;14:254–61.
3. Solass W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized
intraperitoneal aerosol chemotherapy (PIPAC): occupational
health and safety aspects. Ann Surg Oncol 2013;20:3504–11.
4. Graversen M, Pedersen P, Mortensen MB. Environmental safety
during the administration of pressurized intraperitoneal aerosol
chemotherapy. Pleura and Peritoneum 2016;1:203–8.
5. Blanco A, Giger-Pabst U, Solass W, Zieren J, Reymond MA. Renal
and hepatic toxicities after pressurized intraperitoneal aerosol
chemotherapy (PIPAC). Ann Surg Oncol 2013;20:2311–6.
6. Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W,
Reymond MA. Pressurized Intraperitoneal aerosol chemotherapy
(PIPAC) with low-dose cisplatin and doxorubicin in gastric peri-
toneal metastasis. J Gastrointestinal Surg: Off J Soc Surg
Alimentary Tract 2016;20:367–73.
7. Tempfer CB, Winnekendonk G, Solass W, Horvat R, Giger-Pabst
U, Zieren J, et al. Pressurized intraperitoneal aerosol che-
motherapy in women with recurrent ovarian cancer: A phase 2
study. Gynecol Oncol 2015;137:223–8.
8. Grass F, Vuagniaux A, Teixeira-Farinha H, Lehmann K, Demartines
N, Hubner M. Systematic review of pressurized intraperitoneal
aerosol chemotherapy for the treatment of advanced peritoneal
carcinomatosis. Br J Surg 2017;104:669–78.
9. Nowacki M, Alyami M, Villeneuve L, Mercier F, Hubner M, Willaert
W, et al. Multicenter comprehensive methodological and technical
analysis of 832 pressurized intraperitoneal aerosol chemotherapy
(PIPAC) interventions performed in 349 patients for peritoneal
carcinomatosis treatment: an international survey study. Eur J
Surg Oncol 2018. https://doi.org/10.1016/j.ejso.2018.02.014.
10. Solass W, Sempoux C, Detlefsen S, Carr NJ, Bibeau F.
Peritoneal sampling and histological assessment of thera-
peutic response in peritoneal metastasis: proposal of the
peritoneal regression grading score (PRGS). Pleura and
Peritoneum 2016;1:99–107.
11. Badgwell B, Cormier JN, Krishnan S, Yao J, Staerkel GA,
Lupo PJ, et al. Does neoadjuvant treatment for gastric cancer
patients with positive peritoneal cytology at staging laparo-
scopy improve survival? Ann Surg Oncol 2008;15:
2684–91.
12. Michielsen K, Vergote I, Op De Beeck K, Amant F, Leunen K,
Moerman P, et al. Whole-body MRI with diffusion-weighted
sequence for staging of patients with suspected ovarian cancer:
a clinical feasibility study in comparison to CT and FDG-PET/CT.
Eur Radiol 2014;24:889–901.
13. Low RN, Barone RM. Combined diffusion-weighted and gadoli-
nium-enhanced MRI can accurately predict the peritoneal can-
cer index preoperatively in patients being considered for
cytoreductive surgical procedures. Ann Surg Oncol
2012;19:1394–401.
14. Low RN, Barone RM, Lucero J. Comparison of MRI and CT for
predicting the peritoneal cancer index (PCI) preoperatively in
patients being considered for cytoreductive surgical proce-
dures. Ann Surg Oncol 2015;22:1708–15.
15. Sun K, Chen S, Xu J, Li G, He Y. The prognostic significance of
the prognostic nutritional index in cancer: a systematic review
and meta-analysis. J Cancer Res Clin Oncol
2014;140:1537–49.
16. Jiang N, Deng JY, Ding XW, Ke B, Liu N, Zhang RP, et al.
Prognostic nutritional index predicts postoperative complica-
tions and long-term outcomes of gastric cancer. Wjg
2014;20:10537–44.
17. Nozoe T, Ninomiya M, Maeda T, Matsukuma A, Nakashima H,
Ezaki T. Prognostic nutritional index: a tool to predict the bio-
logical aggressiveness of gastric carcinoma. Surg Today
2010;40:440–3.
18. Bottomley A, Aaronson NK. International perspective on health-
related quality-of-life research in cancer clinical trials: the eur-
opean organisation for research and treatment of cancer
experience. J Clin Oncol 2007;25:5082–6.
19. Chang HH, Leeper WR, Chan G, Quan D, Driman DK. Infarct-like
necrosis: a distinct form of necrosis seen in colorectal carci-
noma liver metastases treated with perioperative chemother-
apy. Am J Surg Pathol 2012;36:570–6.
6 Graversen et al.: PIPAC treatment in patients with peritoneal carcinomatosis
Brought to you by | University Library of Southern Denmark - Syddansk Universitetsbibliotek
Authenticated
Download Date | 10/29/18 9:16 AM
